ermolayxitpev.blogspot.com
June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: today announced that , Chairman, Chievf Executive Officer and Presidentof InterMune, will present at the Goldman Sacha 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET. To accessz a live audio webcast ofthe presentation, investors and othet interested parties may log on to the investor relationw page of InterMune's corporate website at . The company recommends loggingg on to the site 15 minutes prio to the start of the presentation in order to register or download anynecessary software.
InterMunee is a biotechnology company focusef onthe research, development and commercializatiohn of innovative therapies in pulmonology and hepatology. InterMune has a pipelind portfolio addressing idiopathic pulmonary fibrosis and hepatitis Cvirus (HCV) The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluatiny pirfenidone as a possible therapeutic candidatde for the treatment of patients with IPF, an open-label extension study from CAPACITY and a research prograk focused on small molecules for the treatment of pulmonaru disease.
The hepatology portfolio includes the HCV proteaser inhibitorcompound ITMN-191 (referred to as R72277 at Roche, its development partner) in Phase 1b, a second-generatiom HCV protease inhibitor research and a research program evaluating new targets in For additional information about InterMune and its R&D please visit . SOURCE InterMune, Inc.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment